Navigation Links
NeurogesX to Present at Roth 2008 OC Growth Stock Conference
Date:2/19/2008

SAN MATEO, Calif., Feb. 19 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing novel pain management therapies, announced today that it is scheduled to present at the Roth Capital Partners 20th Annual OC Growth Stock Conference in Laguna Niguel, CA on February 20, 2008. Anthony DiTonno, President and Chief Executive Officer, will be presenting and Stephen Ghiglieri, Chief Financial Officer, will be available to respond to questions during the break out session.

Event: Roth Capital 20th Annual OC Growth Stock Conference

Date: Wednesday, February 20, 2008

Time: 2:00 p.m. Pacific Time

Place: Ritz Carlton, Laguna Niguel, CA (Salon 3)

An audio Web cast of the Company's presentation will be available by going to the investor relations section of NeurogesX' Web site at http://www.neurogesx.com. A replay of the presentation will be available for 15 days.

About NeurogesX, Inc.

NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused on developing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy. NeurogesX' late stage product portfolio is led by its product candidate NGX-4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions, that the company believes offers significant advantages over other pain therapies. Three Phase 3 clinical trials with NGX-4010 have been completed and have met their primary endpoints, two in PHN and one in painful HIV-DSP.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, the timing of presentations by NeurogesX and the expected benefits of NeurogesX' potential products, including its lead product candidate NGX-4010. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, past results of clinical trials may not be indicative of future clinical trials results; NeurogesX' product candidate may have unexpected adverse side effects or inadequate therapeutic efficacy; positive results in clinical trials may not be sufficient to obtain FDA or European regulatory approval; physician or patient reluctance to use NGX-4010, if approved, or the inability of physicians to obtain sufficient reimbursement for such procedures; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in clinical development, obtaining regulatory approval, market acceptance and commercialization of NGX-4010 and the advantages of NGX-4010 over other pain therapies. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.

NeurogesX The Ruth Group

Stephen Ghiglieri Investors / Media

(650) 358-3310 Stephanie Carrington / Jason Rando

sghiglieri@neurogesx.com (646) 536-7017 / 7025

scarrington@theruthgroup.com

jrando@theruthgroup.com


'/>"/>
SOURCE NeurogesX, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NeurogesX to Present at the 10th Annual BIO CEO & Investor Conference
2. NeurogesX Closes $25 Million Private Placement
3. NeurogesX, Inc. Announces $25 Million Private Placement
4. NeurogesX to Present at Lazard Capital Markets Healthcare Conference
5. NeurogesX to Present at CIBC World Markets 18th Annual Healthcare Conference and Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. NeurogesX Expands Senior Management Team
7. NeurogesX to Present at UBS 2007 Global Life Sciences Conference
8. NeurogesX Appoints New Director to the Board
9. NeurogesX to Present at BioCenturys NewsMakers in the Biotech Industry Conference
10. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
11. AspenBio Pharma to Present at the Roth Capital Partners 20th Annual Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... According to a report by Transparency Market ... due to the presence of a large pool of participants; however, ... , and Sigma-Aldrich, compete with each other in this market. With ... than 76% of this market in 2016.  ... As of now, a large number of ...
(Date:3/23/2017)... 2017 In today,s pre-market research, ... the Biotech industry: Sangamo Therapeutics Inc. (NASDAQ: SGMO), Eyegate ... SYN), and Regulus Therapeutics Inc. (NASDAQ: RGLS ... Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from "Market Weight." Learn ... at: ...
(Date:3/22/2017)... 22, 2017 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today ... (RGC), U.K. Biobank and GSK to generate genetic sequence data ... The initiative will enable researchers to gain valuable insights to ... wide range of serious and life threatening diseases. ... Genetic evidence ...
(Date:3/22/2017)... , March 22, 2017  Ascendis Pharma A/S ... innovative TransCon technology to address significant unmet medical ... for the full year ended December 31, 2016. ... for our company as we broadened our pipeline ... integrated rare disease company with an initial focus ...
Breaking Biology Technology:
(Date:3/2/2017)... March 2, 2017 Summary This report ... and its partnering interests and activities since 2010. ... Read the full ... Alliance since 2010 report provides an in-depth insight into the ... companies. On demand company reports are prepared upon ...
(Date:3/2/2017)... 2017 Australian stem cell and regenerative medicine ... signed an agreement with the Monash Lung Biology Network, ... Institute and Department of Pharmacology at Monash University, ... study to support the use of Cymerus™ mesenchymal stem ... Asthma is a chronic, long term lung condition ...
(Date:2/28/2017)... , February 28, 2017 News solutions for ... ... from 14 to 16 March, Materna will present ... show how seamless travel is a real benefit for passengers. ... biometrics to their passenger touch point solutions to take passengers through ...
Breaking Biology News(10 mins):